Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The novel substituted pyrimidine, KP544, reduces motor deficits in the R6/2 transgenic mouse model of Huntington's disease.

Restorative neurology and neuroscience - 1 Jan 2007

Dey Nicholas D, Boersen Angela J, Myers Rebecca A, York Lynae R, Bombard Matthew C, Lu Ming, Sandstrom Michael I, Hulce Verne D, Lescaudron Laurent, Dunbar Gary L

Abstract excerpt

PURPOSE: The purpose of this study was to test the potential therapeutic effects of the substituted pyrimidine, KP544, which has been shown to amplify the effects of nerve growth factor in vitro, on motor deficits in the R6/2 transgenic mouse model of Huntington's disease (HD). METHODS: Young, female R6/2 mice were given daily oral intubation of either 10 mg/kg KP544 or vehicle (0.5% methylcellulose) at 6 weeks...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cyclohexanols
Share to Exploratory Behavior

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Huntington Disease

Share to Motor Activity

Share to Motor Skills

Share to Movement Disorders

Share to Pyrimidines

Share to Reaction Time

Source

Identifiers

PMID: 18334766

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The novel substituted pyrimidine, KP544, reduces motor deficits in the R6/2 transgenic mouse model of Huntington's disease.PMID 18334766Read ↗

Brief ampakine treatments slow the progression of Huntington's disease phenotypes in R6/2 mice.Semantic proximity Read ↗

Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation.Semantic proximity Read ↗

CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6/2 mice.Semantic proximity Read ↗

Longitudinal analysis of the behavioural phenotype in R6/1 (C57BL/6J) Huntington's disease transgenic mice.Semantic proximity Read ↗

XJB-5-131-mediated improvement in physiology and behaviour of the R6/2 mouse model of Huntington's disease is age- and sex- dependent.Semantic proximity Read ↗

ABHD6 inhibition rescues a sex-dependent deficit in motor coordination in the HdhQ200/200 mouse model of Huntington’s diseaseSemantic proximity Read ↗

Early behavioral deficits in R6/2 mice suitable for use in preclinical drug testing.Semantic proximity Read ↗

Environmental enrichment slows disease progression in R6/2 Huntington's disease mice.Semantic proximity Read ↗

Chronic lithium chloride treatment has variable effects on motor behaviour and survival of mice transgenic for the Huntington's disease mutation.Semantic proximity Read ↗

The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model.Semantic proximity Read ↗

Force-plate quantification of progressive behavioral deficits in the R6/2 mouse model of Huntington's disease.Semantic proximity Read ↗

Brain-derived neurotrophic factor over-expression in the forebrain ameliorates Huntington's disease phenotypes in mice.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.